Browsing Tag
Sanofi
75 posts
What makes molecular clamp technology attractive for future combination respiratory vaccines?
Can molecular clamp technology make combination respiratory vaccines more practical than mRNA? Learn how Sanofi plans to use it for multi-pathogen protection.
Is Sanofi creating a template for biopharma bolt-on deals with its Vicebio acquisition?
Is Sanofi setting a new standard for biopharma bolt-on deals with its $1.15B Vicebio acquisition? Find out how this strategy could shape future M&A.
Will Vicebio’s VXB-241 and VXB-251 give Sanofi an edge in older adult respiratory protection?
Can Sanofi’s VXB-241 and VXB-251 vaccines protect older adults better than single-pathogen RSV shots? Explore how they could reshape respiratory care.
Can Sanofi’s molecular clamp bet with Vicebio challenge mRNA leaders in respiratory vaccines?
Can Sanofi’s $1.15B Vicebio deal challenge Pfizer and Moderna’s mRNA RSV dominance? Explore how molecular clamp vaccines could change respiratory protection.
Sanofi to acquire Vicebio in $1.15bn deal to expand RSV and hMPV vaccine pipeline
Sanofi doubles down on vaccines and rare immunology with Vicebio and Blueprint acquisitions. Find out how these deals could reshape its growth strategy.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Sanofi’s $9.5bn buyout of Blueprint Medicines signals high-stakes immunology expansion
Sanofi’s $9.5B Blueprint Medicines acquisition strengthens its rare disease pipeline with Ayvakit and signals deeper investment in immunology.
Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy
Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline.
Viz.ai partners with Sanofi and Regeneron to use AI for advancing COPD care across U.S. hospitals
Viz.ai teams up with Sanofi and Regeneron to launch AI-powered COPD care module for faster diagnosis, better outcomes, and real-time care coordination.
Novavax shares rally after FDA approves non-mRNA COVID-19 vaccine for at-risk groups
Novavax stock surged 25% after FDA approved its non-mRNA COVID-19 vaccine Nuvaxovid. Find out what triggered this rally and what it means for investors.